Detomidine is an imidazole derivative and α2-adrenergic receptor agonist,
Currently, detomidine is licensed for use only in horses in the United States, but it is also licensed for use in cattle in Europe and Australia.
Properties
Detomidine is a sedative with
analgesic properties.
α
2-adrenergic receptor agonists produce dose-dependent sedative and analgesic effects, mediated by activation of α
2 catecholamine receptors, thus inducing a negative feedback response, reducing production of excitatory neurotransmitters. Due to inhibition of the sympathetic nervous system, detomidine also has cardiac and respiratory effects and an
antidiuretic action.
Effects
A profound lethargy and characteristic lowering of the head with reduced sensitivity to environmental stimuli are seen with detomidine. A short period of reduced coordination is characteristically followed by immobility and a firm stance with front legs spread. Following administration there is an initial increase in
blood pressure, followed by
bradycardia and second degree atrioventricular block (this is not
Pathology in horses). The horse commonly
to excess, especially on the flanks and neck. Other side effects reported include
piloerection (hair standing erect),
ataxia,
salivation, slight muscle tremors, and, rarely, penile prolapse.
Uses
Sedation and anesthetic
premedication in horses and other large animals, commonly combined with
butorphanol for increased analgesia and depth of sedation. In conjunction with
ketamine it may also be used for intravenous
anaesthesia of short duration.
The drug is normally administered by the intravenous route, and is fastest and most efficient when given intravenously. However, in recalcitrant animals, detomidine may be administered by the intramuscular or sublingual routes. The dose range advised by the manufacturers is 20–40 μg/kg intravenous for moderate sedation, but this dose may need to be higher if given intramuscularly.
When given intravenously, detomidine usually takes effect in 2–5 minutes, and recovery is full within 30–60 minutes. However, this is highly dependent upon the dosage, environment, and the individual animal; some horses are highly resistant to sedation.
Cautions
As detomidine is an
arrhythmogenic agent, extreme care should be exercised in horses with cardiac disease, and in the concurrent administration of other arrhythmogenics. The concurrent use of potentiated sulfonamide
antibiotics is considered particularly dangerous.
Anesthetic recoveries in horses that have received ketamine following a detomidine premedication are often violent with the horse having multiple failures to stand, resulting in Injury to itself. Xylazine is a superior premedication, with ketamine resulting in safer recoveries.
See also
External links
